Current Evidence Supporting Associations of DNA Methylation Measurements with Survivorship Burdens in Cancer Survivors: A Scoping Review

Overview

Journal Cancer Med

Specialty Oncology

Date 2024 Jul 4

PMID 38963018

Authors

Michael Sayer

Ding Quan Ng

Raymond Chan

Kord Kober

Alexandre Chan

Affiliations

Soon will be listed here.

Abstract

Introduction: Identifying reliable biomarkers that reflect cancer survivorship symptoms remains a challenge for researchers. DNA methylation (DNAm) measurements reflecting epigenetic changes caused by anti-cancer therapy may provide needed insights. Given lack of consensus describing utilization of DNAm data to predict survivorship issues, a review evaluating the current landscape is warranted.

Objective: Provide an overview of current studies examining associations of DNAm with survivorship burdens in cancer survivors.

Methods: A literature review was conducted including studies if they focused on cohorts of cancer survivors, utilized peripheral blood cell DNAm data, and evaluated the associations of DNAm and survivorship issues.

Results: A total of 22 studies were identified, with majority focused on breast (n = 7) or childhood cancer (n = 9) survivors, and half studies included less than 100 patients (n = 11). Survivorship issues evaluated included those related to neurocognition (n = 5), psychiatric health (n = 3), general wellness (n = 9), chronic conditions (n = 5), and treatment specific toxicities (n = 4). Studies evaluated epigenetic age metrics (n = 10) and DNAm levels at individual CpG sites or regions (n = 12) for their associations with survivorship issues in cancer survivors along with relevant confounding factors. Significant associations of measured DNAm in the peripheral blood samples of cancer survivors and survivorship issues were identified.

Discussion/conclusion: Studies utilizing epigenetic age metrics and differential methylation analysis demonstrated significant associations of DNAm measurements with survivorship burdens. Associations were observed encompassing diverse survivorship outcomes and timeframes relative to anti-cancer therapy initiation. These findings underscore the potential of these measurements as useful biomarkers in survivorship care and research.

Citing Articles

Cancer history and accelerated aging: findings from a nationally representative sample in the US.

Han X, Ogongo M, Tian F, Zhao J, Zheng Z, Liu Z Cancer Causes Control. 2024; .

PMID: 39633205 DOI: 10.1007/s10552-024-01941-w.

References

Zombeck J, Fey E, Lyng G, Sonis S . A clinically translatable mouse model for chemotherapy-related fatigue. Comp Med. 2013; 63(6):491-7. PMC: 3866991. View

Maass S, Brandenbarg D, Boerman L, Verhaak P, de Bock G, Berendsen A . Fatigue among Long-Term Breast Cancer Survivors: A Controlled Cross-Sectional Study. Cancers (Basel). 2021; 13(6). PMC: 8001130. DOI: 10.3390/cancers13061301. View

Fransquet P, Lacaze P, Saffery R, Phung J, Parker E, Shah R . Blood DNA methylation signatures to detect dementia prior to overt clinical symptoms. Alzheimers Dement (Amst). 2020; 12(1):e12056. PMC: 7346866. DOI: 10.1002/dad2.12056. View

Fairman C, Lonbro S, Cardaci T, VanderVeen B, Nilsen T, Murphy A . Muscle wasting in cancer: opportunities and challenges for exercise in clinical cancer trials. JCSM Rapid Commun. 2022; 5(1):52-67. PMC: 9481195. DOI: 10.1002/rco2.56. View

Lu A, Quach A, Wilson J, Reiner A, Aviv A, Raj K . DNA methylation GrimAge strongly predicts lifespan and healthspan. Aging (Albany NY). 2019; 11(2):303-327. PMC: 6366976. DOI: 10.18632/aging.101684. View

Horvath S, Oshima J, Martin G, Lu A, Quach A, Cohen H . Epigenetic clock for skin and blood cells applied to Hutchinson Gilford Progeria Syndrome and studies. Aging (Albany NY). 2018; 10(7):1758-1775. PMC: 6075434. DOI: 10.18632/aging.101508. View

Story Jovanova O, Nedeljkovic I, Spieler D, Walker R, Liu C, Luciano M . DNA Methylation Signatures of Depressive Symptoms in Middle-aged and Elderly Persons: Meta-analysis of Multiethnic Epigenome-wide Studies. JAMA Psychiatry. 2018; 75(9):949-959. PMC: 6142917. DOI: 10.1001/jamapsychiatry.2018.1725. View

Jaffe A, Irizarry R . Accounting for cellular heterogeneity is critical in epigenome-wide association studies. Genome Biol. 2014; 15(2):R31. PMC: 4053810. DOI: 10.1186/gb-2014-15-2-r31. View

Gehle S, Kleissler D, Heiling H, Deal A, Xu Z, Miller V . Accelerated epigenetic aging and myopenia in young adult cancer survivors. Cancer Med. 2023; 12(11):12149-12160. PMC: 10278459. DOI: 10.1002/cam4.5908. View

10.

Plonski N, Chen C, Dong Q, Qin N, Song N, Parikh H . Epigenetic Age in Peripheral Blood Among Children, Adolescent, and Adult Survivors of Childhood Cancer. JAMA Netw Open. 2023; 6(4):e2310325. PMC: 10148192. DOI: 10.1001/jamanetworkopen.2023.10325. View

11.

Krieger N, Chen J, Testa C, Roux A, Tilling K, Watkins S . Use of Correct and Incorrect Methods of Accounting for Age in Studies of Epigenetic Accelerated Aging: Implications and Recommendations for Best Practices. Am J Epidemiol. 2023; 192(5):800-811. PMC: 10160768. DOI: 10.1093/aje/kwad025. View

12.

Fardell J, Irwin C, Vardy J, Bell M . Anxiety, depression, and concentration in cancer survivors: National Health and Nutrition Examination Survey results. Support Care Cancer. 2023; 31(5):272. PMC: 10105664. DOI: 10.1007/s00520-023-07710-w. View

13.

Song M, Seffernick A, Archer K, Mori K, Park S, Chang L . Race/ethnicity-associated blood DNA methylation differences between Japanese and European American women: an exploratory study. Clin Epigenetics. 2021; 13(1):188. PMC: 8507376. DOI: 10.1186/s13148-021-01171-w. View

14.

Adam S, Doege D, Koch-Gallenkamp L, Thong M, Bertram H, Eberle A . Age-specific health-related quality of life in disease-free long-term prostate cancer survivors versus male population controls-results from a population-based study. Support Care Cancer. 2019; 28(6):2875-2885. DOI: 10.1007/s00520-019-05120-5. View

15.

Palma-Gudiel H, Fananas L, Horvath S, Zannas A . Psychosocial stress and epigenetic aging. Int Rev Neurobiol. 2020; 150:107-128. DOI: 10.1016/bs.irn.2019.10.020. View

16.

Kresovich J, OBrien K, Xu Z, Weinberg C, Sandler D, Taylor J . Changes in methylation-based aging in women who do and do not develop breast cancer. J Natl Cancer Inst. 2023; 115(11):1329-1336. PMC: 10637033. DOI: 10.1093/jnci/djad117. View

17.

Agha G, Mendelson M, Ward-Caviness C, Joehanes R, Huan T, Gondalia R . Blood Leukocyte DNA Methylation Predicts Risk of Future Myocardial Infarction and Coronary Heart Disease. Circulation. 2019; 140(8):645-657. PMC: 6812683. DOI: 10.1161/CIRCULATIONAHA.118.039357. View

18.

Flanagan J, Wilson A, Koo C, Masrour N, Gallon J, Loomis E . Platinum-Based Chemotherapy Induces Methylation Changes in Blood DNA Associated with Overall Survival in Patients with Ovarian Cancer. Clin Cancer Res. 2016; 23(9):2213-2222. DOI: 10.1158/1078-0432.CCR-16-1754. View

19.

Bhakta N, Liu Q, Ness K, Baassiri M, Eissa H, Yeo F . The cumulative burden of surviving childhood cancer: an initial report from the St Jude Lifetime Cohort Study (SJLIFE). Lancet. 2017; 390(10112):2569-2582. PMC: 5798235. DOI: 10.1016/S0140-6736(17)31610-0. View

20.

Hillary R, Stevenson A, McCartney D, Campbell A, Walker R, Howard D . Epigenetic measures of ageing predict the prevalence and incidence of leading causes of death and disease burden. Clin Epigenetics. 2020; 12(1):115. PMC: 7394682. DOI: 10.1186/s13148-020-00905-6. View